Glaukos Licenses First-in-Class Tri-Specific Biologic for Retinal Diseases
GKOS has more than doubled off its 52-week low of $73.16 on elevated volume (1.9× avg).
Summary
Glaukos signed an exclusive license with RevOpsis Therapeutics for RO-104, a first-in-class tri-specific biologic targeting VEGF-A, VEGF-C, and Ang-2 for nAMD, DME, DR, and RVO. The deal also grants exclusive rights to RevOpsis' RevMod platform for up to four additional retinal candidates. Financial terms were not disclosed. This expands Glaukos' retinal pipeline beyond its glaucoma and corneal franchises, adding a differentiated mechanism with preclinical superiority claims versus approved anti-VEGF therapies. The agreement follows positive three-year Epioxa data reported yesterday, reinforcing the company's retinal R&D momentum.
At the time of this announcement, GKOS was trading at $173.55 on NYSE in the Life Sciences sector, with a market capitalization of approximately $10.2B. The 52-week trading range was $73.16 to $191.62. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.